EICHOR
● Active Not Recruiting
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
Condition: Carcinoma, Renal Cell · Sponsor: Merck Sharp & Dohme LLC
About this study
Substudy 03B is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03B is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with advanced second line plus (2L+) clear cell renal cell carcinoma (ccRCC). This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to demonstrate a tolerable safety profile for the combination of investigational agents. There will be no hypothesis testing in this study.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (51)
| University of California at San Francisco ( Site 3008) | San Francisco, California, United States | — |
| Yale-New Haven Hospital-Yale Cancer Center ( Site 3011) | New Haven, Connecticut, United States | — |
| University of Chicago ( Site 3013) | Chicago, Illinois, United States | — |
| University of Iowa ( Site 3012) | Iowa City, Iowa, United States | — |
| Henry Ford Health System ( Site 3014) | Detroit, Michigan, United States | — |
| Laura and Isaac Perlmutter Cancer Center ( Site 3016) | New York, New York, United States | — |
| Memorial Sloan Kettering Cancer Center ( Site 3002) | New York, New York, United States | — |
| Duke Cancer Institute ( Site 3015) | Durham, North Carolina, United States | — |
| UPMC Cancer Center/Hillman Cancer Center ( Site 3017) | Pittsburgh, Pennsylvania, United States | — |
| Vanderbilt University Medical Center ( Site 3004) | Nashville, Tennessee, United States | — |
| UTSW Medical Center ( Site 3003) | Dallas, Texas, United States | — |
| Blacktown Hospital ( Site 3601) | Blacktown, New South Wales, Australia | — |
+ 39 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04626518